RECENT POSTS
Wednesday, August 21, 2019
WeWork Liabilities, Part II

Tuesday, August 20, 2019
WeWork’s Liabilities in Perspective

Wednesday, August 14, 2019
Comparing LinkedIn, Twitter Revenue

Wednesday, August 7, 2019
Leasing’s Effect on Retail Balance Sheets

Thursday, August 1, 2019
Using Calcbench to Find China Exposure

Tuesday, July 30, 2019
Leasing Details: The Comcast Example

Monday, July 29, 2019
Easy Fundamental Equity Analysis in Python

Monday, July 22, 2019
Calcbench Data and Tax Reform Insight

Wednesday, July 17, 2019
Downshifting in the Trucking World

Tuesday, July 16, 2019
New Report: Adoption of New Lease Accounting Standard

Friday, July 5, 2019
More Consequences of Lease Accounting

Monday, July 1, 2019
Another Example of Tax Reform Twisting Bottom Line

Thursday, June 27, 2019
The Latest Share Repurchase Data

Tuesday, June 18, 2019
Popping the Lid on Smuckers’ Goodwill

Tuesday, June 11, 2019
Not Much Fizz in LaCroix Right Now

Wednesday, May 29, 2019
An Example of Calcbench, Excel, and Insight

Monday, May 20, 2019
Research Paper: Capex Spending

Thursday, May 16, 2019
Psst: Got Any Weed?

Wednesday, May 15, 2019
Open Letter: SEC Proposed Rule for BDCs

Friday, May 10, 2019
General Motors and Workhorse

Archive  |  Search:
R&D Spending on the Rise, 2013-2016
Monday, March 13, 2017

Good news for science and math majors: Corporate America is spending more to keep you busy.

Calcbench looked at reported research & development spending among the S&P 500 the other day for the years 2013 through 2016. By just about every definition, the numbers look good. R&D spending is up among the group in absolute dollars, and as a percentage of revenue. Average spending per filer is also up, both in dollar terms and as a percentage of revenue. And more companies are disclosing R&D spending within our sample of 428 companies that had filed their 2016 reports as of March 13.

In other words: yay science!

First let’s look at the bigger picture. Below is a chart of R&D spending for the whole population fo 428 filers for the last four years.

Next, let’s remember that only 170 companies in our sample reported any R&D expenditures at all in 2016; the rest didn’t. And while the number of filers reporting R&D costs has risen in the last few years, that rise actually is quite small: up from 167 filers in 2013.

In other words, all those companies reporting no R&D spending pull down the average numbers quite a lot. So let’s cut those science no-shows loose, and look at the sub-group of purists keeping it real since 11th grade chemistry class. Their numbers below. The total R&D numbers are the same (because we only stripped out the zero-dollar filers), but the averages are now much higher.

Lastly, we decided to rank 2016 filers by R&D spending as a percentage of revenue, and then R&D spending in absolute dollars—with (perhaps to little surprise) wildly different results. Here are the top 10 spenders as a percent of revenue:

Almost all are pharmacuetical companies. That’s expected; most pharmaceutical companies spend boatloads on research before they even get a drug to market and see their first dime of revenue. Once a drug does reach market, the odds of it becoming a blockbuster are still slim.

Now let’s look at the top 10 in terms of absolute dollars:

This time only three pharmaceutical companies crack the top 10 (Merck, Pfizer, and Johnson & Johnson), and naturally Google leads the whole bunch—Google being Google and all.

As more filers submit their 2016 reports in coming weeks and months, we’ll do a more in-depth analysis of R&D. For now, however, if investing in research dollars is an omen of future growth and a brighter society, the omens are pointing in the right direction.


FREE Calcbench Premium
Two Week Trial

Research Financial & Accounting Data Like Never Before. More features and try our Excel add-in. Sign up now to try the Premium Suite.